PF-03463275

DB11993InvestigationalSmall molecule

PF-03463275 has been used in trials studying the treatment of Schizophrenia and Cognitive Impairments Associated With Schizophrenia.

Mechanism: Pharmacologically active on Sodium- and chloride-dependent glycine transporter 1
Curator reviewed
Formula / weight: C₁₉H₂₂ClFN₄O · 376.86 g/mol (avg)
Code names: PF-03463275

Resolves to

Compound

Structure

InChIKeyKYLOBHXXQOZRKK-FICVDOATSA-NSMILES[H][C@@]12CN(C)C[C@]1([H])[C@H]2CN(CC1=CC(Cl)=C(F)C=C1)C(=O)C1=CN(C)C=N1

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with PF-03463275, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.